Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraorbital vs Oral Steroid in Idiopathic Orbital Inflammation
NCT03958344Phase 3Unknown
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triamcinolone and betamethasone in Idiopathic Orbital Inflammation (IOI) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Number of recurrences at 6 months, Duration of remission at 6 months and 1 more. Status: unknown.
02
Drugs
triamcinolonebetamethasone
03
Conditions
Idiopathic Orbital Inflammation (IOI)
Beyond the preview
Go deeper on NCT03958344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958344.